Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Applies for SEP-190 for Insomnia
December 13, 2010
- Acotiamide to Drive Zeria's Global Business
December 13, 2010
- Early Price Settlement Unlikely: Mr Minari of Nihon Chouzai
December 13, 2010
- Kyowa Hakko Bio's Hofu Facility Complies with GMP Requirements: Korosho
December 13, 2010
- Teijin to Extend Pharma Business by Launching Feburic, Synvisc: Mr Ohyagi
December 13, 2010
- Qol to Open More Convenience Stores with Dispensing Services
December 13, 2010
- Ranbaxy Launches Generic Aricept in the US
December 13, 2010
- Blopress Returns to Top Place in 3rd Qtr: IMS Japan
December 13, 2010
- M3 Acquires EMS Research in the UK
December 13, 2010
- Hospira Japan Launches Its 1st In-house Oncology Generics
December 13, 2010
- Astellas Obtains Oncology Technology Platform from AVEO
December 13, 2010
- Itochu, PRISM BioLab to Market Library of Chemical Compounds
December 13, 2010
- Generics Should Be Priced at Lower Levels in Japan: Dr Eiki of Bayer Yakuhin
December 13, 2010
- Sawai to Re-Propose Merger to Kyorin
December 13, 2010
- Bayer, Regeneron to Apply for VEGF Trap-Eye in Europe, US in 2011
December 13, 2010
- Eisai to Donate Antifilarial Drug through WHO
December 13, 2010
- Global Players Accelerate Personnel Downsizing
December 13, 2010
- Takeda to Apply for Hematide in US in 2Q 2011
December 13, 2010
- “Vaccine Gap” in Japan Needs Immediate Resolution: Prof. Plotkin
December 13, 2010
- Develop More Drugs for Cancer, Hereditary Diseases: Mr Inoue
December 13, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…